Goldman Sachs Downgraded Novo Nordisk A/S (NVO)

Novo Nordisk A/S (NYSE:NVO) was downgraded by Goldman Sachs from a “conviction-buy” rating to a “buy” rating in a report issued on Tuesday, The Fly reports.

Novo Nordisk A/S (NYSE:NVO) opened at 50.91 on Tuesday. Novo Nordisk A/S has a 52-week low of $46.17 and a 52-week high of $60.34. The company has a market capitalization of $129.53 billion and a PE ratio of 25.05. The firm’s 50-day moving average is $54.34 and its 200-day moving average is $54.56.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Friday, April 29th. The company reported $0.57 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.53 by $0.04. On average, equities research analysts forecast that Novo Nordisk A/S will post $2.29 EPS for the current year.

10 Safe Dividend Stocks for the Second Quarter

These stocks have been paying their shareholders for a long time With the U.S. stock market fresh off its first quarterly loss si...